These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 29530933

  • 21. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A, Lazaridis G, Koliou GA, Kouvatseas G, Christodoulou C, Pectasides D, Kotoula V, Batistatou A, Bobos M, Tsolaki E, Papadopoulou K, Pentheroudakis G, Papakostas P, Pervana S, Petraki K, Chrisafi S, Razis E, Psyrri A, Bafaloukos D, Kalogeras KT, Kalofonos HP, Fountzilas G.
    PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
    [Abstract] [Full Text] [Related]

  • 22. The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
    Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ.
    Oncotarget; 2016 Nov 15; 7(46):75518-75525. PubMed ID: 27776352
    [Abstract] [Full Text] [Related]

  • 23. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A, International Breast Cancer Study Group.
    Cancer; 2003 Apr 01; 97(7):1591-600. PubMed ID: 12655514
    [Abstract] [Full Text] [Related]

  • 24. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
    Kotoula V, Tsakiri K, Koliou GA, Lazaridis G, Papadopoulou K, Giannoulatou E, Tikas I, Christodoulou C, Chatzopoulos K, Bobos M, Pentheroudakis G, Tsolaki E, Batistatou A, Kotsakis A, Koutras A, Linardou H, Razis E, Res E, Pectasides D, Fountzilas G.
    Clin Breast Cancer; 2019 Apr 01; 19(2):113-125.e4. PubMed ID: 30545790
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
    Jankowski C, Guiu S, Cortet M, Charon-Barra C, Desmoulins I, Lorgis V, Arnould L, Fumoleau P, Coudert B, Rouzier R, Coutant C, Reyal F.
    Breast Cancer Res Treat; 2017 Jan 01; 161(1):73-81. PubMed ID: 27807808
    [Abstract] [Full Text] [Related]

  • 27. Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials.
    Chen L, Zhou W, Hu X, Yi M, Ye C, Yao G.
    Cancer Treat Rev; 2019 May 01; 75():12-19. PubMed ID: 30856373
    [Abstract] [Full Text] [Related]

  • 28. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A, Kos T, Avci N, Cubukcu E, Olmez OF, Bulut N, Degirmenci M.
    Asian Pac J Cancer Prev; 2015 May 01; 16(4):1643-9. PubMed ID: 25743846
    [Abstract] [Full Text] [Related]

  • 29. Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis.
    Stewart P, Blanchette P, Shah PS, Ye XY, Boldt RG, Fernandes R, Vandenberg T, Raphael J.
    Breast; 2020 Dec 01; 54():203-210. PubMed ID: 33130486
    [Abstract] [Full Text] [Related]

  • 30. Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer.
    Okutur K, Bassulu N, Dalar L, Aydin K, Bozkurt M, Pilanci KN, Dogusoy GB, Tecimer C, Mandel NM, Demir G.
    Asian Pac J Cancer Prev; 2015 Dec 01; 16(7):2645-51. PubMed ID: 25854340
    [Abstract] [Full Text] [Related]

  • 31. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
    Gori S, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, Pinotti G, Gubiotti M, Cavazzini MG, Turazza M, Duranti S, De Simone V, Iezzi L, Bisagni G, Spazzapan S, Cavanna L, Saggia C, Bria E, Cretella E, Vici P, Santini D, Fabi A, Garrone O, Frassoldati A, Amaducci L, Saracchini S, Evangelisti L, Barni S, Gamucci T, Mentuccia L, Laudadio L, Zoboli A, Marchetti F, Bogina G, Lunardi G, Boni L.
    PLoS One; 2015 Dec 01; 10(9):e0136731. PubMed ID: 26340098
    [Abstract] [Full Text] [Related]

  • 32. Trastuzumab and survival of patients with metastatic breast cancer.
    Kast K, Schoffer O, Link T, Forberger A, Petzold A, Niedostatek A, Werner C, Klug SJ, Werner A, Gatzweiler A, Richter B, Baretton G, Wimberger P.
    Arch Gynecol Obstet; 2017 Aug 01; 296(2):303-312. PubMed ID: 28616827
    [Abstract] [Full Text] [Related]

  • 33. Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin).
    Schmidt M, KÜmmel S, Ruf-Doerdelmann A, Distelrath A, Wacker J, Schmatloch S, Busch-Liles S, LÜdtke-Heckenkamp K.
    Anticancer Res; 2021 Jan 01; 41(1):485-496. PubMed ID: 33419847
    [Abstract] [Full Text] [Related]

  • 34. MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
    Gogas H, Kotoula V, Alexopoulou Z, Christodoulou C, Kostopoulos I, Bobos M, Raptou G, Charalambous E, Tsolaki E, Xanthakis I, Pentheroudakis G, Koutras A, Bafaloukos D, Papakostas P, Aravantinos G, Psyrri A, Petraki K, Kalogeras KT, Pectasides D, Fountzilas G.
    J Transl Med; 2016 May 17; 14(1):136. PubMed ID: 27184134
    [Abstract] [Full Text] [Related]

  • 35. Cyclin D1, p16(INK) (4A) and p27(Kip1) in pancreatic adenocarcinoma: assessing prognostic implications through quantitative image analysis.
    Georgiadou D, Sergentanis TN, Sakellariou S, Filippakis GM, Zagouri F, Vlachodimitropoulos D, Psaltopoulou T, Lazaris AC, Patsouris E, Zografos GC.
    APMIS; 2014 Dec 17; 122(12):1230-9. PubMed ID: 25053516
    [Abstract] [Full Text] [Related]

  • 36. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
    Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D.
    Lancet Oncol; 2013 Mar 17; 14(3):244-8. PubMed ID: 23414588
    [Abstract] [Full Text] [Related]

  • 37. HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.
    Xu QQ, Pan B, Wang CJ, Zhou YD, Mao F, Lin Y, Guan JH, Shen SJ, Zhang XH, Xu YL, Zhong Y, Wang XJ, Zhang YN, Sun Q.
    Oncotarget; 2016 Sep 27; 7(39):63571-63582. PubMed ID: 27566580
    [Abstract] [Full Text] [Related]

  • 38. Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.
    Caparica R, Ma Y, De Angelis C, Richard F, Desmedt C, Awada A, Piccart M, Perez EA, Moreno-Aspitia A, Badve S, Thompson EA, de Azambuja E.
    Clin Breast Cancer; 2022 Jun 27; 22(4):308-318. PubMed ID: 34980541
    [Abstract] [Full Text] [Related]

  • 39. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
    Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G.
    Oncotarget; 2016 Aug 30; 7(35):56295-56308. PubMed ID: 27462779
    [Abstract] [Full Text] [Related]

  • 40. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
    Chen W, Wei F, Xu J, Wang Y, Chen L, Wang J, Guan X.
    Int J Mol Med; 2011 Dec 30; 28(6):985-91. PubMed ID: 21887460
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.